Evidence map›Paper›PMID 40730954›Full record

ArticleBMC medical research methodology2025

Power and sample size considerations for test-negative design with bias correction: a case study on the world first malaria vaccine.

Yura K Ko, Tobias Alfvén, Daisuke Yoneoka

Abstract read
In one paragraph

Article in BMC medical research methodology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yura K KoDepartment of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden. yongra.ko@ki.se.
Tobias AlfvénDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Daisuke YoneokaCenter for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTest-negative design (TND) studies are increasingly common in evaluating vaccine effectiveness (VE) for various infectious diseases. TND studies are susceptible to bias due to disease outcome misclassification caused by imperfect test sensitivity and specificity. Several bias correction methods have been proposed. However, sample size or power considerations for TND studies incorporating bias correction for such misclassification have not yet been investigated.

methodsWe used Monte Carlo simulations to assess how bias correction affects the statistical power and sample size for VE estimation in TND studies. Simulations were conducted under varying levels of diagnostic test sensitivities (60%, 80%, and 95%). Bias correction was implemented using the multiple over-imputation method, which accounts for test misclassification through a parametric bootstrapping approach. Using a malaria vaccine as an example, we defined six vaccination status categories based on the time since receipt of the third or fourth vaccine dose. In the simulated target population, vaccination coverage was assumed to be low (< 10%) except for the group vaccinated more than 12 months after dose 4. We assumed relatively low VE (< 50%) against clinical malaria cases and a 30% malaria positivity rate among unvaccinated individuals presenting with malaria-related symptoms. Statistical power to detect VE was estimated for each vaccination status, both with and without bias correction.

resultsEstimated VEs based on observed data were consistently underestimated across all vaccination status groups due to diagnostic misclassification. In contrast, bias-corrected estimates were approximately unbiased but displayed wider confidence intervals, with their precision decreasing at lower test sensitivities. Statistical power to detect VE declined substantially when diagnostic test sensitivity was low. For instance, at 80% sensitivity, only three vaccination status groups reached 80% power with a sample size of 10,000, whereas the same power was achieved with just 6,000 individuals under a perfect test.

conclusionsBias due to imperfect diagnostic testing can substantially reduce the power of TND studies. Power calculations should account for outcome misclassification and potential correction methods. Failure to do so may lead to underpowered studies and misleading VE estimates.

Indexed as

MalariaMalaria VaccinesResearch DesignVaccine EfficacyBiasComputer SimulationHumansMonte Carlo MethodSample SizeSensitivity and SpecificityMalaria VaccinesBias correctionMalariaSample sizeStatistical powerTest negative designVaccine effectiveness

Identifiers

PMID40730954
PMCPMC12309064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.